Mesoblast Limited
MESO · NASDAQ
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $17,198 | $5,902 | $7,501 | $10,211 |
| % Growth | 191.4% | -21.3% | -26.5% | – |
| Cost of Goods Sold | $5,130 | $41,070 | $54,922 | $63,572 |
| Gross Profit | $12,068 | -$35,168 | -$47,421 | -$53,361 |
| % Margin | 70.2% | -595.9% | -632.2% | -522.6% |
| R&D Expenses | $34,807 | $25,353 | $27,189 | $32,815 |
| G&A Expenses | $23,207 | $23,626 | $25,374 | $27,210 |
| SG&A Expenses | $39,309 | $23,626 | $53,107 | $57,967 |
| Sales & Mktg Exp. | $16,102 | $0 | $27,733 | $30,757 |
| Other Operating Expenses | $395 | $0 | $0 | $30,760 |
| Operating Expenses | $74,511 | $48,979 | $76,790 | $90,785 |
| Operating Income | -$62,443 | -$84,147 | -$69,289 | -$80,574 |
| % Margin | -363.1% | -1,425.7% | -923.7% | -789.1% |
| Other Income/Exp. Net | -$39,369 | -$4,000 | -$12,812 | -$10,479 |
| Pre-Tax Income | -$101,812 | -$88,147 | -$82,101 | -$91,586 |
| Tax Expense | $330 | -$191 | -$212 | -$239 |
| Net Income | -$102,142 | -$87,956 | -$81,889 | -$91,347 |
| % Margin | -593.9% | -1,490.3% | -1,091.7% | -894.6% |
| EPS | -0.84 | -0.89 | -0.98 | -1.3 |
| % Growth | 5.6% | 9.2% | 24.6% | – |
| EPS Diluted | -0.84 | -0.89 | -0.98 | -1.3 |
| Weighted Avg Shares Out | 120,779 | 98,671 | 83,773 | 68,271 |
| Weighted Avg Shares Out Dil | 120,779 | 98,670 | 83,926 | 68,286 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3,554 | $1,824 | $831 | $0 |
| Interest Expense | $22,929 | $20,658 | $19,444 | $17,288 |
| Depreciation & Amortization | $6,400 | $1,895 | $4,107 | $4,380 |
| EBITDA | -$73,659 | -$56,077 | -$58,550 | -$76,573 |
| % Margin | -428.3% | -950.1% | -780.6% | -749.9% |